Allarity Therapeutics, Inc.
ALLR · XNASCIK 1860657fmd_034M438PRG4W5S62JM24EV94MRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 0 | 0 |
| Net interest income | – | (1) | – | – | – | – |
| Realized investment gains (losses) | 1 | (0) | (0) | – | – | – |
| Gross profit | – | – | (2) | – | – | – |
| Research and development | 4 | 14 | 7 | 7 | 6 | 7 |
| Total operating expenses | 8 | 27 | 34 | 17 | 27 | 13 |
| Operating income | (8) | (27) | (34) | (17) | (27) | (13) |
| Interest expense | 0 | 0 | 0 | 0 | 1 | 0 |
| Interest and investment income | – | – | 0 | 0 | 1 | 1 |
| Other non-operating income (expense) | 2 | 0 | 17 | 5 | 2 | 1 |
| Income before taxes | – | – | (18) | (12) | (25) | (11) |
| Income tax expense | 0 | 0 | (2) | 0 | (0) | 0 |
| Net income from continuing operations | – | – | (16) | (12) | (25) | (11) |
| Net income | (7) | (27) | (16) | (12) | (25) | (11) |
| Net income to common shareholders | (7) | (27) | (21) | (20) | (25) | (11) |